KG
Therapeutic Areas
OmniAb Pipeline
| Drug | Indication | Phase |
|---|---|---|
| JNJ-81201887 (via Janssen) | Plaque Psoriasis | Approved |
| LN-144 (via Iovance) | Advanced Melanoma | BLA Submitted |
| Multiple Partner Programs | Various (Oncology, Immunology, etc.) | Phase I to Phase III |
Leadership Team at OmniAb
MW
Matthew W. Foehr
Chief Executive Officer & President
CB
Charles Berkman, JD
Chief Legal Officer & Secretary
YA
Yasmina Abdiche, PhD
Senior Vice President, Exploratory Research
CR
Carolyn R. Bertozzi, PhD
Board Chair
JC
Jennifer Cochran, PhD
Board Member
SC
Steve Crouse
Board Member